Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986013 | 0.91 | MEN1 (0.46) | KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL986300 | 0.91 | CDK9 (0.39) | MDM4CD38HTR7KMT2AIRAK4 | |
| SCHEMBL984790 | 0.91 | PAK1 (0.38) | BTKMDM4PAK1HTR7KMT2A | |
| SCHEMBL985290 | 0.91 | KDM5A (0.37) | BTKMDM4PAK1HTR7KMT2A | |
| SCHEMBL982969 | 0.91 | BRD4 (0.39) | CD38HTR7KMT2AIRAK4MEN1 | |
| SCHEMBL982008 | 0.90 | BTK (0.40) | BTKKMT2A | |
| SCHEMBL983123 | 0.90 | PARP1 (0.45) | BTKKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL981807 | 0.90 | MDM4 (0.38) | BTKMDM4PAK1CD38KMT2A | |
| SCHEMBL981754 | 0.89 | MCHR1 (0.37) | BTKPAK1CD38JAK2IRAK4 | |
| SCHEMBL984887 | 0.88 | HPGDS (0.44) | MDM4PAK1CD38KMT2AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | BTK 1977/4885MDM4 2898/4885PAK1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.